Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01589393
Other study ID # CIHR-2009
Secondary ID
Status Completed
Phase N/A
First received April 26, 2012
Last updated March 20, 2018
Start date September 2010
Est. completion date December 2013

Study information

Verified date April 2012
Source McMaster University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Victims of trauma with severe head injury who have bled into their brains are at high risk of developing blood clots in their legs. These blood clots can break off and travel through the bloodstream to the lungs causing death. Blood thinners can be given to patients to prevent blood clots from developing but this can leave patients at risk for additional bleeding in the brain causing further damage or death. The earlier blood thinners are started the more effective they are at preventing blood clots but some patients with severe head injury who have bled into their brains will develop further bleeding even if they do not receive blood thinners. Even though a growing body of research has shown that the majority of bleeding in the brain stops within the first 24 hours after injury and that it is safe to start blood thinners as early as 24 hours after injury, doctors are still waiting longer than 4 days to start blood thinners in these patients over concerns of worsening bleeding. In Canada, almost half of the patients with severe head injury do not receive blood thinners until at least five days after injury. Delays in starting blood thinners appear to put patients at increased risk of developing blood clots, unnecessarily. This study will compare the benefits of starting low-molecular weight heparin (LMWH), a type of blood thinner, early (less than 48 hours) versus the current practice (waiting until the 5th day after being injured) in preventing blood clots in patients who have bled into their brains after severe head injury. The investigators believe that starting LMWH earlier will be more effective in preventing blood clots without worsening any bleeding when compared to waiting to start blood thinners. This study is called OPTTTICH (Optimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage) and will be the largest Canadian investigator-initiated randomized control trial on blood clot prevention in trauma patients with severe head injury who have bled into their brains.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date December 2013
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria:

1. Multi-system trauma patients referred to the trauma service with a non-progressing tICH documented on 24-hour repeat head CT scan

Exclusion Criteria:

1. Less than 16 years of age

2. Unexpected to survive or to remain in hospital >72 hours

3. Known malignancy under active care at time of admission

4. Known DVT, PE, or other condition requiring anticoagulation at time of admission

5. Coagulopathy (defined as international normalized ratio (INR) values >1.5 times the upper limit of normal, or partial thromboplastin time (PTT) values >1.5 times the upper limit of normal) at 24 hours after admission

6. Platelet count <75 x 109/L at 24 hours after admission

7. Bilateral lower limb amputation

8. History of allergy to heparin or suspected or proven HIT

9. Limitation of life support or palliative care

10. Prior enrolment in this trial or currently in a confounding randomized trial

11. Pregnancy

12. Study drug (LMWH or placebo) not administered within 36-48 hours post-injury

13. Grade V liver or splenic injuries that have not received definitive care (e.g. embolization, surgical intervention) within 36-48 hours after injury

14. Persistent intracranial pressure >20 mm Hg

15. Spinal subdural haematoma or spinal epidural haematoma

16. Intracranial haemorrhage progression on 24-hour repeat CT head scan

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Enoxaparin
Enoxaparin 30 mg subcutaneously twice daily for six doses starting 36-48 hours post traumatic injury.
Other:
Placebo
0.9% normal saline in equal volume to active comparator given subcutaneously twice daily starting 36-48 hours post traumatic injury for six doses.

Locations

Country Name City State
Canada Hamilton Health Sciences- General site Hamilton Ontario

Sponsors (2)

Lead Sponsor Collaborator
McMaster University Canadian Institutes of Health Research (CIHR)

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proximal lower limb deep vein thrombosis (DVT) diagnosed by bilateral lower extremity compression ultrasound. Ultrasounds will be performed within 72 hours of enrollment as well as twice weekly when in ICU and weekly thereafter. Non-compressibility of 1 or more proximal deep venous segments on compression US will be considered diagnostic. Each segment will be assessed as fully compressible, partially compressible, not compressible, or not well visualized. All positive ultrasounds will be recorded and stratified into above knee (proximal DVT) or below knee (distal DVT). Patients who have both proximal and distal vein thrombus will be classified as having proximal DVT. Maximum of 60 days or until hospital discharge.
Secondary Non-intracranial bleeding Non-intracranial bleeding events will be recorded and classified as either major or minor bleeding, according to a modified bleeding assessment tool adapted to our patient population. Maximum of 60 days or until hospital discharge.
Secondary Pulmonary Embolism Patients who develop clinical suspsicion of PE will have a helical CT chest. Pulmonary embolism will be diagnosed by the presence of an intraluminal filling defect detected in either the main,lobar,or segmental branches of the pulmonary artery. Patients with a high probability of PE on clinical grounds but with negative CT chest will undergo a ventilation-perfusion scan. Maximum of 60 days or until hospital discharge
Secondary Intracranial haemorrhage progression (IHP). If a Patient develops clinical evidence of neurological deterioration an emergent head CT scan will be performed.The CT scan will be reviewed by the blinded attending neuroradiologist. A comparison to the previous CT scan will be made and assessed for evidence of IHP. Intracranial haemorrhage progression will be defined as either 1) the development of a new haematoma, 2) any enlargement of an existing haematoma by an attending neuroradiologist's CT report, or 3) any progression of haematoma by the Marshall Head CT Classification System. Maximum of 60 days or until hospital discharge.
See also
  Status Clinical Trial Phase
Recruiting NCT02260908 - OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage - Pilot Study N/A
Not yet recruiting NCT06322953 - Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage Phase 3